Applied DNA Schedules Fiscal 2019 Second Quarter Financial Results Conference Call for Thursday, May 9, 2019 at 4:30 PM ET
May 02 2019 - 4:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it
plans to release financial results for its fiscal 2019 second
quarter ended March 31, 2019 after market close on Thursday, May 9,
2019. In conjunction with the release, the Company has scheduled a
conference call at 4:30 p.m. Eastern Time that will also be
broadcast live over the Internet.
What:
Applied DNA’s Fiscal 2019 Second Quarter Financial
Results Conference Call
When:
Thursday, May 9, 2019, at 4:30 p.m. Eastern Time
Where:
Via phone by dialing +1 844-887-9402 or +1
412-317-6798 and ask to join the Applied DNA call; via webcast.
A telephonic replay of the conference call will be available for
one day and may be accessed by calling +1 877-344-7529 or +1
412-317-0088 with the passcode 10130964. The webcast will be
archived within the ‘Events and Presentations’ portion of the
‘Investors’ page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA including the substantial doubt relating to the
Company’s ability to continue as a going concern. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, future
clinical data and analysis, including whether any of Applied DNA’s
product candidates will advance further in preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, shifting enforcement
priorities of US federal laws relating to cannabis, and various
other factors detailed from time to time in Applied DNA's SEC
reports and filings, including our Annual Report on Form 10-K filed
on December 18, 2018 and our subsequent quarterly report on 10-Q
filed on February 7, 2019, and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190502005114/en/
Investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.comWeb:
www.adnas.comTwitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024